AMPLY Discovery applies a biology-first, AI-powered platform to mine multi-omic and genomic datasets—extending into non-coding regions—to uncover disease-relevant signals and rapidly prioritise therapeutic candidates. The company then validates these signals through iterative laboratory testing, producing high-quality programmes positioned for licensing or collaboration. Spun out of Queen’s University Belfast, AMPLY operates a portfolio model that generates multiple discovery programmes in areas of high unmet need and drives them to clear, partner-ready inflection points. Its recent recruitment of Dr Oliver Rausch, former Head of Biology at Storm Therapeutics, as Chief Scientific Officer strengthens the firm’s expertise in RNA biology and oncology drug discovery. AMPLY is intentionally structured for partnering, aiming to supply differentiated oncology assets to larger biopharma companies. Financially, the company has secured a strategic investment from Keeps Biomed to accelerate its oncology pipeline; no further operating metrics were disclosed.

Total raised

$4M

Funding rounds

3

Latest round

Seed

Latest activity

May 2025